“Alzinova: Another external validation”

Date: 2021-01-18

In a Research Note posted last week, equity research and investment banking company, Redeye, commented on “another external validation” of the Aβ concept to treat Alzheimer’s disease patients.

In the note, analyst, Anders Hedlund, says, “There are now several drug candidates targeting Aβ that have shown efficacy signals. It provides a validation of the Aβ hypothesis generally and for Alzinova’s vaccine approach specifically.”

He adds, “We see room for a more favorable valuation once in the clinic. Alzinova would then be a clinical biotech case with a vaccine candidate that distinguishes in the pipeline, in an indication (Alzheimer’s) which perhaps holds the largest unmet medical need at present.”

Click here to read the full Redeye Research Note.